BriaCell Therapeutics Corp. (OTCMKTS:BCTXF – Get Free Report)’s stock price traded down 5.6% during trading on Wednesday . The company traded as low as $2.19 and last traded at $2.19. 22,628 shares traded hands during mid-day trading, an increase of 1,117% from the average session volume of 1,859 shares. The stock had previously closed at $2.32.
BriaCell Therapeutics Stock Performance
The firm has a market cap of $1.69 million, a P/E ratio of -0.57 and a beta of 1.09. The business’s 50-day simple moving average is $2.88 and its 200 day simple moving average is $3.97.
BriaCell Therapeutics Company Profile
BriaCell Therapeutics Corp. operates as a clinical-stage biotechnology company that specializes in immunotherapy for advanced breast cancer. It is advancing its targeted immunotherapy program by conducting a Phase I/IIA clinical trial with Bria-IMT in combination with an immune checkpoint inhibitor and a companion diagnostic test, BriaDx, to identify patients to benefit from Bria-IMT.
See Also
- Five stocks we like better than BriaCell Therapeutics
- 3 Fintech Stocks With Good 2021 Prospects
- High-Yield Texas Instruments Could Hit New Highs Soon
- Insider Buying Explained: What Investors Need to Know
- Pagaya Technologies: An AI Fintech That Insiders Are Buying
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Higher Oil Prices Could Give NextEra’s Stock Earnings a Boost
Receive News & Ratings for BriaCell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BriaCell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
